Literature DB >> 21817854

Transcutaneous and intradermal vaccination.

Behazine Combadiere1, Christelle Liard.   

Abstract

Most vaccines are administered by intramuscular (i.m.) or subcutaneous (s.c.) routes, however, intradermal (i.d.) and transcutaneous (t.c.) techniques are regaining popularity. We will discuss in this review several factors that strongly justify the use of the cutaneous tissues and development of alternative methods for vaccination. That includes (1) our improved knowledge of skin physiology and better understanding of the barrier role of the horny layer, (2) the rationalization for targeting the different cutaneous layers, i.e. the epidermis, dermis, or hypodermis, (3) our advances in knowledge of the skin immune system, especially the plasticity of antigen-presenting cells (APCs) (i.e Langerhans cells (LC), dermal dendritic cells (DDC) and dermal macrophages) in the induction of immune responses, (4) the reduction of antigenic dose for some modes of cutaneous administration, (5) the increased need in needlefree vaccination strategies for developing countries to cope with blood contamination issues. Progress in skin immunization methods and better understanding of skin immunity allow proposing innovative and efficient vaccination strategies against infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21817854     DOI: 10.4161/hv.7.8.16274

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  53 in total

1.  Transdermal immunization using solid-in-oil nanodispersion with CpG oligodeoxynucleotide adjuvants.

Authors:  Momoko Kitaoka; Ayaka Naritomi; Yuya Hirakawa; Noriho Kamiya; Masahiro Goto
Journal:  Pharm Res       Date:  2014-11-01       Impact factor: 4.200

Review 2.  An update on the use of laser technology in skin vaccination.

Authors:  Xinyuan Chen; Ji Wang; Dilip Shah; Mei X Wu
Journal:  Expert Rev Vaccines       Date:  2013-10-16       Impact factor: 5.217

3.  Comparison of Models for Bubonic Plague Reveals Unique Pathogen Adaptations to the Dermis.

Authors:  Rodrigo J Gonzalez; Eric H Weening; M Chelsea Lane; Virginia L Miller
Journal:  Infect Immun       Date:  2015-05-04       Impact factor: 3.441

Review 4.  Tailored immunity by skin antigen-presenting cells.

Authors:  Clement Levin; Helene Perrin; Behazine Combadiere
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

5.  Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination.

Authors:  Eléna Gonçalves; Olivia Bonduelle; Angèle Soria; Pierre Loulergue; Alexandra Rousseau; Marine Cachanado; Henri Bonnabau; Rodolphe Thiebaut; Nicolas Tchitchek; Sylvie Behillil; Sylvie van der Werf; Annika Vogt; Tabassome Simon; Odile Launay; Behazine Combadière
Journal:  J Clin Invest       Date:  2019-03-07       Impact factor: 14.808

6.  Facilitation of transcutaneous drug delivery and vaccine immunization by a safe laser technology.

Authors:  Xinyuan Chen; Dilip Shah; Garuna Kositratna; Dieter Manstein; Richard R Anderson; Mei X Wu
Journal:  J Control Release       Date:  2012-01-09       Impact factor: 9.776

7.  Characterization of pandemic influenza immune memory signature after vaccination or infection.

Authors:  Olivia Bonduelle; Fabrice Carrat; Charles-Edouard Luyt; Catherine Leport; Anne Mosnier; Nora Benhabiles; Anne Krivine; Flore Rozenberg; Nora Yahia; Assia Samri; Dominique Rousset; Sylvie van der Werf; Brigitte Autran; Behazine Combadiere
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

8.  Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.

Authors:  Jamie F S Mann; Paul F McKay; Anezka Fiserova; Katja Klein; Alethea Cope; Paul Rogers; Julie Swales; Michael S Seaman; Behazine Combadiere; Robin J Shattock
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

9.  Evaluation of the Immunogenicity and Protective Efficacy of an Enterotoxigenic Escherichia coli CFA/I Adhesin-Heat-Labile Toxin Chimera.

Authors:  Aisling O'Dowd; Milton Maciel; Steven T Poole; Michael G Jobling; Julianne E Rollenhagen; Colleen M Woods; Stephanie A Sincock; Annette L McVeigh; Michael J Gregory; Ryan C Maves; Michael G Prouty; Randall K Holmes; Stephen J Savarino
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

Review 10.  Intanza (®) 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age.

Authors:  Isabel Leroux-Roels; Françoise Weber
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.